Click on headlines below to download research

Tuzistra XR steady growth in Rx run rate
Vernalis | 19/07/2017

Vernalis has provided a year-end trading and operational update ahead of its FY17 results due to be announced on 12 September. Total revenues are expected…

FDA issues CCP-07 complete response letter
Vernalis | 24/04/2017

FDA has issued a complete response letter (CRL) to Vernalis’ CCP-07 NDA following its 20 April PDUFA date, outlining questions that need to be addressed…

Positive Tuzistra trends
Vernalis | 15/03/2017

Investment into addressing barriers to higher Tuzistra XR prescribing is starting to translate into higher prescription (Rx) rates. Mid-way through the…